柴胡疏肝汤合枸橼酸坦度螺酮治疗躯体化障碍的临床研究
|
摘要
目的观察柴胡疏肝汤合枸橼酸坦度螺酮治疗躯体化障碍的临床疗效。方法将130例躯体化障碍病人随机分为两组,对照组运用枸橼酸坦度螺酮治疗,研究组运用柴胡疏肝汤合枸橼酸坦度螺酮治疗,疗程为4周。观察两组治疗前后症状自评量表(SCL-90)、汉密尔顿抑郁量表(HAMD)评分变化以及临床疗效。结果治疗4周后,研究组愈显率为69.23%,对照组愈显率为38.46%,研究组愈显率高于对照组(P <0.05)。治疗4周后,两组SCL-90各因子评分、HAMD评分均降低;且研究组SCL-90各因子评分、HAMD评分低于对照组(P <0.05)。结论柴胡疏肝汤合枸橼酸坦度螺酮治疗躯体化障碍优于单用枸橼酸坦度螺酮治疗。
Objective To observe the effect of Chaihu Shugan decoction(CSD)and tandospirone citrate in the treatment of somatizationdisorder.Methods One hundred and thirty patients with somatization disorder were randomly divided into two groups:control group trea-ted with tandospirone citrate,and treatment group treated with CSD and tandospirone citrate for 4 weeks.The Symptoms Checklist 90(SCL-90),Hamilton Depression Scale(HAMD)scores and clinical efficacy were observed before and after treatment.Results After 4 weeks of treatment,The total effective rate was significantly higher in treatment group than that in control group(69.23%vs 38.46%,P <0.05).The scores of SCL-90 and HAMD were decreased in two groups,which were lower in treatment group than those in the controlgroup(P <0.05).Conclusion The effect of CSD and tandospirone citrate for the treatment of somatization disorder is superior to tan-conate citrate alone.
Objective To observe the effect of Chaihu Shugan decoction(CSD)and tandospirone citrate in the treatment of somatizationdisorder.Methods One hundred and thirty patients with somatization disorder were randomly divided into two groups:control group trea-ted with tandospirone citrate,and treatment group treated with CSD and tandospirone citrate for 4 weeks.The Symptoms Checklist 90(SCL-90),Hamilton Depression Scale(HAMD)scores and clinical efficacy were observed before and after treatment.Results After 4 weeks of treatment,The total effective rate was significantly higher in treatment group than that in control group(69.23%vs 38.46%,P <0.05).The scores of SCL-90 and HAMD were decreased in two groups,which were lower in treatment group than those in the controlgroup(P <0.05).Conclusion The effect of CSD and tandospirone citrate for the treatment of somatization disorder is superior to tan-conate citrate alone.
引文
[1]姚玉芳,胡波.躯体化障碍的临床特征、治疗及临床转归研究[J].国际精神病学杂志,2011,38(1):10.
[2]中华医学会精神科分会.中国精神障碍分类方案与诊断标准[M].3版.济南:山东科学技术出版社,2011:118-119.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:353.
[4]FORD C V.Somatoform and factitious disorder[J].Treatments of Psychiatric Disorders,2001,23(2):1731-1824.
[5]RIEF W,PILGER F,IHLE D,et al.Emmunological difference between patients with major depression and somatization syndrome[J].Psychiatry Res,2001,105(3):165-174.
[6]李宁,叶兰仙.躯体化障碍的发病机制及诊治的研究进展[J].精神医学杂志,2013,26(2):152-153.
[7]王娜.刘华玲.右佐匹克隆联合枸橼酸坦度螺酮治疗高血压合并焦虑患者的临床观察[J].临床荟萃,2013,28(9):1051-1052.
[8]毛智群,李达,张国富,等.枸橼酸坦度螺酮联合米氮平治疗老年期抑郁症的对照研究[J].中国健康心理学杂志,2012,20(9):1314-1316.
[9]储新娟,肖伟衷,李清华,等.枸橼酸坦度螺酮胶囊治疗神经性头痛50例[J].现代生物医学进展,2015,15(9):1718-1719.
[10]田德禄.中医内科学[M].北京:人民卫生出版社,2002:126-127.
[11]薛秀娟,吴中秋,吴颂.运用疏肝解郁养心化痰祛瘀法治疗躯体化障碍的探讨[J].河北中医,2012,34(2):280-282.
[12]王玉杰.疏肝健脾方与肝郁脾虚证相关的研究[J].北京中医药大学,2010,15(11):105-107.
[13]戈宏焱.柴胡皂苷抗抑郁作用及其机制的研究[D].长春:吉林大学,2010.
[14]李书启.柴胡疏肝散抗氧化活性及其活性成分柚皮苷药代动力学的研究[D].北京:北京化工大学,2010.
[15]李云辉,张春虎,王素娥,等.柴胡疏肝散对慢性应激抑郁模型大鼠行为及血浆促肾上腺皮质激素释放激素和促肾上腺皮质激素的影响[J].中西医结合学报,2009,7(11):1073-1077.
[16]谢鸣,周然.方剂学[M].北京:人民卫生出版社,2002:245.
[17]陈庆玲.运用柴胡疏肝散治疗慢性胃炎的临床疗效观察[J].中国药物经济学,2013(2):630-631.
[18]傅俏芳.柴胡疏肝散加减治疗顽固性失眠60例[J].江西中医药,2012,43(4):39-40.
[19]李满容,杨沁.柴胡疏肝散治疗慢性乙型肝炎肝郁气滞证型的临床观察[J].中国临床研究,2016,8(24):21-22.
[2]中华医学会精神科分会.中国精神障碍分类方案与诊断标准[M].3版.济南:山东科学技术出版社,2011:118-119.
[3]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:353.
[4]FORD C V.Somatoform and factitious disorder[J].Treatments of Psychiatric Disorders,2001,23(2):1731-1824.
[5]RIEF W,PILGER F,IHLE D,et al.Emmunological difference between patients with major depression and somatization syndrome[J].Psychiatry Res,2001,105(3):165-174.
[6]李宁,叶兰仙.躯体化障碍的发病机制及诊治的研究进展[J].精神医学杂志,2013,26(2):152-153.
[7]王娜.刘华玲.右佐匹克隆联合枸橼酸坦度螺酮治疗高血压合并焦虑患者的临床观察[J].临床荟萃,2013,28(9):1051-1052.
[8]毛智群,李达,张国富,等.枸橼酸坦度螺酮联合米氮平治疗老年期抑郁症的对照研究[J].中国健康心理学杂志,2012,20(9):1314-1316.
[9]储新娟,肖伟衷,李清华,等.枸橼酸坦度螺酮胶囊治疗神经性头痛50例[J].现代生物医学进展,2015,15(9):1718-1719.
[10]田德禄.中医内科学[M].北京:人民卫生出版社,2002:126-127.
[11]薛秀娟,吴中秋,吴颂.运用疏肝解郁养心化痰祛瘀法治疗躯体化障碍的探讨[J].河北中医,2012,34(2):280-282.
[12]王玉杰.疏肝健脾方与肝郁脾虚证相关的研究[J].北京中医药大学,2010,15(11):105-107.
[13]戈宏焱.柴胡皂苷抗抑郁作用及其机制的研究[D].长春:吉林大学,2010.
[14]李书启.柴胡疏肝散抗氧化活性及其活性成分柚皮苷药代动力学的研究[D].北京:北京化工大学,2010.
[15]李云辉,张春虎,王素娥,等.柴胡疏肝散对慢性应激抑郁模型大鼠行为及血浆促肾上腺皮质激素释放激素和促肾上腺皮质激素的影响[J].中西医结合学报,2009,7(11):1073-1077.
[16]谢鸣,周然.方剂学[M].北京:人民卫生出版社,2002:245.
[17]陈庆玲.运用柴胡疏肝散治疗慢性胃炎的临床疗效观察[J].中国药物经济学,2013(2):630-631.
[18]傅俏芳.柴胡疏肝散加减治疗顽固性失眠60例[J].江西中医药,2012,43(4):39-40.
[19]李满容,杨沁.柴胡疏肝散治疗慢性乙型肝炎肝郁气滞证型的临床观察[J].中国临床研究,2016,8(24):21-22.